Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Financing Activities (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Cash from Financing Activities for 2 consecutive years, with $35.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 337.28% to $35.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $87.8 million through Dec 2025, up 200.64% year-over-year, with the annual reading at $87.8 million for FY2025, 200.64% up from the prior year.
  • Cash from Financing Activities hit $35.9 million in Q4 2025 for Xilio Therapeutics, up from -$285000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $47.4 million in Q2 2025 to a low of -$285000.0 in Q3 2025.